Chugai Pharmaceutical
Chugai Pharmaceutical Co., Ltd. is a Japanese medicine manufacturer. It is a subsidiary of Hoffmann-La Roche, which owned 62% of the firm as of June 30, 2014. Tokyo is the company's headquarters. The current representative director and chairman is Osamu Nagayama. Tatsuro Kosaka is the current president and CEO of the company.
Chugai has built a global reputation for its proprietary antibody engineering technology, as well as its excellent drug discovery skills, which are supported by a research infrastructure that includes small and mid-size compounds. Chugai also focuses on the creation of novel medications using its patented drug discovery technique in order to gain a better understanding of disease biology. Chugai is the market leader in the Japanese therapeutic antibody market. Chugai is always coming up with new R&D ideas. As a result, the Group's drug discovery capabilities have been highly regarded around the world, with six medications developed by Chugai gaining nine Breakthrough Therapy designations from the United States Food and Drug Administration (FDA).
Under the strategic agreement with Roche, one of the world's leading pharmaceutical corporations, Chugai retains management autonomy. Chugai uses Roche's robust research infrastructure and worldwide development and sales platform to provide breakthrough in-house products to the rest of the globe, in addition to efficiently in-licensing the Roche Group's promising pharmaceuticals for sale in Japan. Since the inception of the strategic agreement, Chugai's product range and development pipeline have expanded as a result of in-licensing Roche goods, and Chugai has gained the No. 1 share of the Japanese cancer market. Chugai may focus its spending on highly inventive proprietary technology and medication research now that it has a steady revenue basis.
Chugai has one of the richest development pipelines in Japan, with projects created in-house and in-licensed from Roche, as well as the technology and systems for efficient and stable production of the ensuing new pharmaceuticals. This supports their ongoing provision of novel medications.
As a pioneer of PHC in Japan, Chugai has contributed to the advancement of this healthcare method, in which treatment plans are tailored to each patient's genetic profile and other criteria. Today, Chugai's efforts include delivering PHC that employs genomic analysis technology as well as contributing to the advancement of cancer genomic medicine in order to usher in the next generation of PHC that delivers more advanced treatments that are tailored to each patient.
Chugai has developed a system for providing solutions that can be precisely tailored to the unique demands of different locations, underpinned by industry-leading safety management and a high degree of expertise in each disease area. Chugai's initiatives to promote multidisciplinary team care and regional healthcare coordination include disseminating information, hosting study sessions, and collaborating with the government on awareness-raising activities. Healthcare providers strongly endorse these approaches.
Founded: March 8, 1943
Headquarters: Nihonbashi Mitsui Tower, Nihonbashi Muromachi 2-1-1, Chūō, Tokyo
Key people: Osamu Nagayama - Chairman and Tatsuro Kosaka - CEO
Website: https://www.chugai-pharm.co.jp/
